ClinicalTrials.gg
TerminatedNCT02511184Updated Jul 1, 2019Results posted

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

A Phase 1 interventional study of Crizotinib and Pembrolizumab in ALK-positive Advanced NSCLC, sponsored by Pfizer. Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-01.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
Decision based on the low enrollment mainly due to high efficacy drugs available in 1st line ALK-positive NSCLC (eg alectinib), not due to any safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
20th of 23
9 · median 80
Started
2015
with 3 others
Phase 1
5 of 23
none open now
Registered
13th of 23
by date
Lead sponsor
9 of 23
Pfizer

Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 20th largest by enrollment, is one of 4 that started in 2015, is one of 5 in phase 1, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About crizotinib

Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.

Read the detailed description

The patients will be screened for up to 28 days before they start treatment to determine if they meet eligibility criteria. The screening procedures will include physical examination, blood work and radiological scans.

In the dose finding phase, patients who meet eligibility criteria will receive crizotinib at the dose level assigned that will be taken on daily basis and pembrolizumab 200 mg intravenous infusion every 3 weeks.

Once a Crizotinib dose level is decided, the dose expansion cohort will start enrolling patients who meet eligibility criteria.

All patients will be followed up every three weeks. Blood samples will be drawn to test for safety and tumor activities and radiological scans will be performed on certain timepoints to determine the antitumor activities.

There will be a quality of life questionnaire administered at certain time points during the study.

The study will have a quality assurance plan that addresses data validation and registry procedures. There is a plan to visit the investigator site for routine monitoring and auditing.

The team will conduct source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms, or interactive voice response systems).

The study will also include a statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives of this study, as specified in the study protocol or statistical plan.

03

Conditions studied

  • ALK-positive Advanced NSCLC

Browse trials for

Keywords

  • crizotinib
  • pembrolizumab
  • ALK-positive NSCLC
  • Lung Cancer
  • ALK-translocated NSCLC
  • Non Small Cell Lung Cancer
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 9 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically or cytologically proved diagnosis of locally advanced recurrent or non-squamous NSCLC that is not suitable for local curative treatment.
  • Alk-positive NSCLC as determined by a test that is approved or validated for use as a companion diagnostic test.
  • No prior systemic therapy for metastatic disease.
  • chemotherapy more than 12 months prior to study enrollment.
  • as per 1.1
  • PS 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to ALK receptor tyrosine kinase inhibitor, anti-PD1, anti-PDL1 or any drug targeting T-cell checkpoint pathways.
  • known diagnosis of immunodeficiency or is receiving systemic therapy or other form of therapy within 7 days of clinical trial treatment.
  • Active disease that has required systemic treatment in the past 3 months.
  • History of extensive disseminated interstitial fibrosis or any grade of interstitial lung disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Dose finding and dose expansion phases

    Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.

    Drug: Crizotinib · Drug: Pembrolizumab

Interventions

  • To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks

  • To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicity (DLT)

    Dose-limiting toxicity (DLT) was defined as any of the following adverse events (AEs) occurring in the first 2 cycles of treatment (6 weeks) which were attributable to crizotinib, pembrolizumab or both: hematologic toxicities including Grade 4 neutropenia, febrile neutropenia, Grade greater than or equal to (\>=) 3 neutropenic infection, Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; non-hematologic toxicities including Grade \>=3 toxicities (non-laboratory), Grade \>=3 nausea, vomiting, or diarrhea despite maximal therapy, non-hematologic Grade \>=3 laboratory value if medical intervention was required to treat the participant or the abnormality led to hospitalization; inability to complete at least 80 percent of the first 2-cycle doses of crizotinib or both infusions of pembrolizumab within the DLT observation period due to treatment-related toxicity. Grade was based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) version 4.03.

    Time frame: 6 weeks

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: 2 years

  2. Objective Response Rate (ORR)

    ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-progressive disease (PD) or not evaluated, and no new lesions. For target lesions, CR: complete disappearance of all target lesions; PR: \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be non-pathological in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.

    Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years

  3. Duration of Response

    Duration of Response (DR) was defined as the time from first documentation of objective tumor response (CR or PR) that was subsequently confirmed, to the first documentation of objective tumor progression or to death on study due to any cause, whichever occurred first.

    Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years

  4. Time to Tumor Response

    Time to Tumor Response (TTR) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed.

    Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years

  5. Progression Free Survival

    Progression Free Survival (PFS) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor progression or death on-study due to any cause, whichever occurred first. For participants who did not have documented objective progression during the study or were alive at last contact, the date of last contact was used.

    Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years

  6. 6-Month, 12-Month and 18-Month Progression Free Survival Probabilities

    PFS probabilities were defined as the probability of being alive and progression free at 6, 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.

    Time frame: Month 6, Month 12, and Month 18

  7. Overall Survival

    Overall Survival (OS) was defined as the time from the first dose of crizotinib or pembrolizumab to the date of death due to any cause. For participants who were alive at last contact, the date of last contact was used.

    Time frame: Day 1 to end of study (for about 2 years)

  8. 12-Month and 18-Month Overall Survival Probabilities

    OS probabilities were defined as the probability of being alive at 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.

    Time frame: Month 12 and Month 18

  9. Number of Participants With Maximum Grade in Laboratory Hematology Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment

    Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, and absolute basophils. Hematology test results were graded by NCI CTCAE version 4.03.

    Time frame: 2 years

  10. Number of Participants With Maximum Grade in Laboratory Chemistry Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment

    Chemistry evaluation included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate, thyroid function tests including thyroid-stimulating hormone, T3 and free T4. Chemistry test results were graded by NCI CTCAE version 4.03.

    Time frame: 2 years

  11. Plasma Concentration Summary of Crizotinib for "Crizotinib + Pembrolizumab" Group

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  12. Plasma Concentration Summary of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  13. Time to Maximum Plasma Concentration (Tmax) of Crizotinib for "Crizotinib + Pembrolizumab" Group

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  14. Time to Maximum Plasma Concentration (Tmax) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  15. Area Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for "Crizotinib + Pembrolizumab" Group

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  16. Area Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  17. Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for "Crizotinib + Pembrolizumab" Group

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  18. Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  19. Apparent Plasma Clearance (CL/F) of Crizotinib for "Crizotinib + Pembrolizumab" Group

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  20. Apparent Plasma Clearance (CL/F) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  21. Plasma Concentration Summary of PF-06260182 for "Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  22. Plasma Concentration Summary of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  23. Time to Maximum Plasma Concentration (Tmax) of PF-06260182 for "Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  24. Time to Maximum Plasma Concentration (Tmax) of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  25. Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for "Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  26. Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  27. Metabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for "Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  28. Metabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  29. Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

  30. Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

    PF-06260182 is a metabolite of crizotinib.

    Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

  31. Serum Concentration of Pembrolizumab

    Time frame: Prior to and at end of pembrolizumab infusion, 120 hours and 336 hours post Day 1 dosing of Cycle 1; pre-dose on Day 1 of Cycles 2, 4,6, 8, 12 and 16; end of Day 1 dosing of Cycle 8; End of Treatment visit

  32. Number of Participants With Programmed Death Receptor-1 Ligand-1 (PD-L1) Expression Level Meeting Pre-defined Criteria

    Archived formalin-fixed, paraffin-embedded tumor issue block was collected at screening. PD-L1 assessment was performed using immunohistochemistry. A sample was considered negative if tumor proportion score was less than 1%; positive if tumor proportion score was greater than or equal to 1%; strong positive if tumor proportion score was greater than or equal to 50%.

    Time frame: Screening

08

Results

Posted Jul 1, 2019
Limitations and caveats
Some of the pre-defined outcome measures could not be analyzed because of premature termination, which was based on low enrollment rate.

Participant flow

Participant flow — Overall Study
MilestoneCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Started27
Completed00
Not completed27
Withdrew: Death10
Withdrew: Lost to follow-up01
Withdrew: Study terminated by sponsor15
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicity (DLT)

Dose-limiting toxicity (DLT) was defined as any of the following adverse events (AEs) occurring in the first 2 cycles of treatment (6 weeks) which were attributable to crizotinib, pembrolizumab or both: hematologic toxicities including Grade 4 neutropenia, febrile neutropenia, Grade greater than or equal to (\>=) 3 neutropenic infection, Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; non-hematologic toxicities including Grade \>=3 toxicities (non-laboratory), Grade \>=3 nausea, vomiting, or diarrhea despite maximal therapy, non-hematologic Grade \>=3 laboratory value if medical intervention was required to treat the participant or the abnormality led to hospitalization; inability to complete at least 80 percent of the first 2-cycle doses of crizotinib or both infusions of pembrolizumab within the DLT observation period due to treatment-related toxicity. Grade was based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) version 4.03.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicity (DLT)
ParticipantsCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Number of Participants With Dose-limiting Toxicity (DLT)22
SecondaryNumber of Participants With Treatment-Emergent Adverse Events

AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
2 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
All-causality AE27
All-causality SAE21
Crizotinib-related AE27
Crizotinib-related SAE00
Pembrolizumab-related AE26
Pembrolizumab-related SAE21
Grade 1 all-causality AE01
Grade 2 all-causality AE02
Grade 3 all-causality AE04
Grade 4 all-causality AE10
Grade 5 all-causality AE10
SecondaryObjective Response Rate (ORR)

ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-progressive disease (PD) or not evaluated, and no new lesions. For target lesions, CR: complete disappearance of all target lesions; PR: \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be non-pathological in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.

Time frame:
Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Objective Response Rate (ORR)5057.1
SecondaryDuration of Response

Duration of Response (DR) was defined as the time from first documentation of objective tumor response (CR or PR) that was subsequently confirmed, to the first documentation of objective tumor progression or to death on study due to any cause, whichever occurred first.

Time frame:
Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
Reported as:
Median · days
Duration of Response
daysCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Duration of Response85 (85 to 85)242 (126 to 339)
SecondaryTime to Tumor Response

Time to Tumor Response (TTR) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed.

Time frame:
Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
Reported as:
Median · days
Time to Tumor Response
daysCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Time to Tumor Response57 (57 to 57)83 (77 to 87)
SecondaryProgression Free Survival

Progression Free Survival (PFS) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor progression or death on-study due to any cause, whichever occurred first. For participants who did not have documented objective progression during the study or were alive at last contact, the date of last contact was used.

Time frame:
Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
Reported as:
Median · days
Progression Free Survival
daysCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Progression Free Survival131.5 (122 to 141)211 (1 to 418)
Secondary6-Month, 12-Month and 18-Month Progression Free Survival Probabilities

PFS probabilities were defined as the probability of being alive and progression free at 6, 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.

Time frame:
Month 6, Month 12, and Month 18

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall Survival (OS) was defined as the time from the first dose of crizotinib or pembrolizumab to the date of death due to any cause. For participants who were alive at last contact, the date of last contact was used.

Time frame:
Day 1 to end of study (for about 2 years)
Reported as:
Median · days
Overall Survival
daysCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Overall Survival452.5 (122 to 783)428 (272 to 730)
Secondary12-Month and 18-Month Overall Survival Probabilities

OS probabilities were defined as the probability of being alive at 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.

Time frame:
Month 12 and Month 18

No measurements were reported for this outcome.

SecondaryNumber of Participants With Maximum Grade in Laboratory Hematology Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment

Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, and absolute basophils. Hematology test results were graded by NCI CTCAE version 4.03.

Time frame:
2 years
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade in Laboratory Hematology Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment
ParticipantsCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Anemia00
Hemoglobin increased00
Lymphocyte count increased00
Lymphopenia02
Absolute neutrophils00
platelets00
White blood cells00
SecondaryNumber of Participants With Maximum Grade in Laboratory Chemistry Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment

Chemistry evaluation included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate, thyroid function tests including thyroid-stimulating hormone, T3 and free T4. Chemistry test results were graded by NCI CTCAE version 4.03.

Time frame:
2 years
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade in Laboratory Chemistry Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment
ParticipantsCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Alanine aminotransferase13
Alkaline phosphatase00
Aspartate aminotransferase11
Total bilirubin00
Creatine kinase00
Creatinine00
Gamma-glutamyl transferase00
Hypercalcemia00
Hyperglycemia01
Hyperkalemia00
Hypermagnesemia00
Hypernatremia00
Hypoalbuminemia00
Hypocalcemia00
Hypoglycemia00
Hypokalemia00
Hypomagnesemia00
Hyponatremia11
Hypophosphatemia01
SecondaryPlasma Concentration Summary of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Reported as:
Median · nanograms/milliliter (ng/mL)
Plasma Concentration Summary of Crizotinib for "Crizotinib + Pembrolizumab" Group
nanograms/milliliter (ng/mL)Crizotinib + Pembrolizumab
Day 1 of Cycle 1: pre-dose0 (0 to 0)
Day 1 of Cycle 2: pre-dose379 (379 to 379)
Day 1 of Cycle 4: pre-dose147 (147 to 147)
Day 1 of Cycle 6: pre-dose235 (235 to 235)
Day 1 of Cycle 8: pre-dose257 (257 to 257)
End of treatment166.04 (8.08 to 324)
SecondaryPlasma Concentration Summary of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Reported as:
Median · ng/mL
Plasma Concentration Summary of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
ng/mLCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Day 15 of monotherapy: pre-dose273 (79.9 to 531)
Day 15 of monotherapy: 1 hour post-dose262.5 (191 to 300)
Day 15 of monotherapy: 2 hours post-dose345 (159 to 455)
Day 15 of monotherapy: 4 hours post-dose331 (133 to 375)
Day 15 of monotherapy: 6 hours post-dose278 (115 to 373)
Day 15 of monotherapy: 8 hours post-dose294.5 (129 to 382)
Day 1 of Cycle 1: pre-dose272.5 (176 to 337)
Day 1 of Cycle 2: pre-dose131 (0.842 to 249)
Day 1 of Cycle 4: pre-dose194.5 (37.5 to 352)
Day 1 of Cycle 6: pre-dose249 (175 to 311)
Day 1 of Cycle 6: 1 hour post-dose272 (184 to 281)
Day 1 of Cycle 6: 2 hours post-dose274 (194 to 497)
Day 1 of Cycle 6: 4 hours post-dose317 (198 to 450)
Day 1 of Cycle 6: 6 hours post-dose301 (172 to 369)
Day 1 of Cycle 6: 8 hours post-dose229.5 (173 to 367)
Day 1 of Cycle 8: pre-dose244.5 (159 to 285)
End of treatment24.65 (0.65 to 489)
SecondaryTime to Maximum Plasma Concentration (Tmax) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryTime to Maximum Plasma Concentration (Tmax) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryApparent Plasma Clearance (CL/F) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryApparent Plasma Clearance (CL/F) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryPlasma Concentration Summary of PF-06260182 for "Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Reported as:
Median · ng/mL
Plasma Concentration Summary of PF-06260182 for "Crizotinib + Pembrolizumab" Group
ng/mLCrizotinib + Pembrolizumab
Day 1 of Cycle 1: pre-dose0 (0 to 0)
Day 1 of Cycle 2: pre-dose182 (182 to 182)
Day 1 of Cycle 4: pre-dose46.4 (46.4 to 46.4)
Day 1 of Cycle 6: pre-dose99.1 (99.1 to 99.1)
Day 1 of Cycle 8: pre-dose67 (67 to 67)
End of treatment56.58 (2.16 to 111)
SecondaryPlasma Concentration Summary of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Reported as:
Median · ng/mL
Plasma Concentration Summary of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
ng/mLCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Day 15 of monotherapy: pre-dose91.35 (28.4 to 148)
Day 15 of monotherapy: 1 hour post-dose74.15 (46.8 to 93.9)
Day 15 of monotherapy: 2 hours post-dose84.3 (52.3 to 141)
Day 15 of monotherapy: 4 hours post-dose107 (53.3 to 117)
Day 15 of monotherapy: 6 hours post-dose91.85 (45.8 to 105)
Day 15 of monotherapy: 8 hours post-dose84.5 (42.5 to 129)
Day 1 of Cycle 1: pre-dose83.2 (40.3 to 107)
Day 1 of Cycle 2: pre-dose21.6 (0 to 65.1)
Day 1 of Cycle 4: pre-dose61.3 (8.55 to 98.3)
Day 1 of Cycle 6: pre-dose74.5 (30.1 to 94.1)
Day 1 of Cycle 6: 1 hour post-dose69.8 (30.8 to 80.6)
Day 1 of Cycle 6: 2 hours post-dose65.8 (40.8 to 144)
Day 1 of Cycle 6: 4 hours post-dose73.3 (31.4 to 158)
Day 1 of Cycle 6: 6 hours post-dose77.7 (38.2 to 139)
Day 1 of Cycle 6: 8 hours post-dose60.6 (38.4 to 111)
Day 1 of Cycle 8: pre-dose62.75 (32.1 to 83.9)
End of treatment2.75 (0 to 112)
SecondaryTime to Maximum Plasma Concentration (Tmax) of PF-06260182 for "Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryTime to Maximum Plasma Concentration (Tmax) of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for "Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryMetabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for "Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryMetabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)

No measurements were reported for this outcome.

SecondaryMetabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Reported as:
Median · ratio
Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib + Pembrolizumab" Group
ratioCrizotinib + Pembrolizumab
Day 1 of Cycle 2: pre-dose0.480 (0.480 to 0.480)
Day 1 of Cycle 4: pre-dose0.316 (0.316 to 0.316)
Day 1 of Cycle 6: pre-dose0.422 (0.422 to 0.422)
Day 1 of Cycle 8: pre-dose0.261 (0.261 to 0.261)
End of treatment0.305 (0.267 to 0.343)
SecondaryMetabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group

PF-06260182 is a metabolite of crizotinib.

Time frame:
Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Reported as:
Median · ratio
Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
ratioCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Day 15 of monotherapy: pre-dose0.334 (0.274 to 0.401)
Day 15 of monotherapy: 1 hour post dose0.275 (0.226 to 0.367)
Day 15 of monotherapy: 2 hours post dose0.307 (0.185 to 0.365)
Day 15 of monotherapy: 4 hours post dose0.321 (0.275 to 0.401)
Day 15 of monotherapy: 6 hours post dose0.330 (0.268 to 0.398)
Day 15 of monotherapy: 8 hours post dose0.311 (0.263 to 0.338)
Day 1 of Cycle 1: pre-dose0.311 (0.229 to 0.376)
Day 1 of Cycle 2: pre-dose0.217 (0 to 0.303)
Day 1 of Cycle 4: pre-dose0.293 (0.228 to 0.355)
Day 1 of Cycle 6: pre-dose0.258 (0.172 to 0.361)
Day 1 of Cycle 6: 1 hour post dose0.249 (0.145 to 0.287)
Day 1 of Cycle 6: 2 hours post dose0.239 (0.210 to 0.290)
Day 1 of Cycle 6: 4 hours post dose0.231 (0.159 to 0.351)
Day 1 of Cycle 6: 6 hours post dose0.258 (0.219 to 0.406)
Day 1 of Cycle 6: 8 hours post dose0.264 (0.212 to 0.302)
Day 1 of Cycle 8: pre-dose0.244 (0.202 to 0.323)
End of treatment0.105 (0 to 0.229)
SecondarySerum Concentration of Pembrolizumab
Time frame:
Prior to and at end of pembrolizumab infusion, 120 hours and 336 hours post Day 1 dosing of Cycle 1; pre-dose on Day 1 of Cycles 2, 4,6, 8, 12 and 16; end of Day 1 dosing of Cycle 8; End of Treatment visit
Reported as:
Median · ng/mL
Serum Concentration of Pembrolizumab
ng/mLCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Day 1 of Cycle 1: pre-dose0 (0 to 0)0 (0 to 0)
Day 1 of Cycle 1: end of infusion63150 (38300 to 88000)61400 (34600 to 102000)
Day 8 of Cycle 1: 120 hours post Day 1 dosing25550 (20600 to 30500)26800 (19100 to 31900)
Day 15 of Cycle 1: 336 hours post Day 1 dosing19600 (14800 to 24400)20100 (11000 to 23700)
Day 1 of Cycle 2: pre-dose9840 (8680 to 11000)15750 (8020 to 19600)
Day 1 of Cycle 4: pre-dose—31600 (18200 to 37300)
Day 1 of Cycle 6: pre-dose—37000 (28500 to 64000)
Day 1 of Cycle 8: pre-dose—38800 (26600 to 64500)
Day 1 of Cycle 8: end of infusion—14300 (11700 to 14500)
Day 1 of Cycle 12: pre-dose—99350 (85700 to 113000)
Day 1 of Cycle 16: pre-dose—29300 (29300 to 29300)
End of treatment10800 (10800 to 10800)27500 (3370 to 45800)
SecondaryNumber of Participants With Programmed Death Receptor-1 Ligand-1 (PD-L1) Expression Level Meeting Pre-defined Criteria

Archived formalin-fixed, paraffin-embedded tumor issue block was collected at screening. PD-L1 assessment was performed using immunohistochemistry. A sample was considered negative if tumor proportion score was less than 1%; positive if tumor proportion score was greater than or equal to 1%; strong positive if tumor proportion score was greater than or equal to 50%.

Time frame:
Screening
Reported as:
Count of participants · Participants
Number of Participants With Programmed Death Receptor-1 Ligand-1 (PD-L1) Expression Level Meeting Pre-defined Criteria
ParticipantsCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
Negative11
Positive13
Strong positive02

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib + Pembrolizumab1/2 (50%)2/2 (100%)2/2 (100%)
Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab0/7 (0%)1/7 (14.3%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
PneumoniaInfections and infestations1/20/7
Alanine aminotransferase increasedInvestigations1/21/7
Aspartate aminotransferase increasedInvestigations1/21/7
PneumonitisRespiratory, thoracic and mediastinal disorders1/20/7
Most frequent other events
Showing 10 of 93
Most frequent other events
EventCrizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + Pembrolizumab
PyrexiaGeneral disorders2/20/7
Alanine aminotransferase increasedInvestigations2/26/7
Aspartate aminotransferase increasedInvestigations2/25/7
DysgeusiaNervous system disorders2/21/7
DiarrhoeaGastrointestinal disorders1/25/7
NauseaGastrointestinal disorders1/25/7
Acute myocardial infarctionCardiac disorders1/20/7
Atrial fibrillationCardiac disorders1/20/7
TachycardiaCardiac disorders1/20/7
Visual impairmentEye disorders1/23/7

Baseline characteristics

Baseline analysis population included all participants enrolled in this study.

Age, Continuous
Age, Continuous(years)Crizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + PembrolizumabTotal
Mean64.5 ± 1256.4 ± 1358.2 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Crizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + PembrolizumabTotal
Female134
Male145
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Crizotinib + PembrolizumabCrizotinib Monotherapy Followed by Crizotinib + PembrolizumabTotal
White257
Asian011
Other011
09

Study locations

15 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham, IDS Pharmacy
    Birmingham, Alabama 35249, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UC San Diego Moores Cancer Center - Investigational Drug Services
    La Jolla, California 92037-0845, United States
  • UC San Diego Medical Center - La Jolla(Thornton Hospital)
    La Jolla, California 92037, United States
  • University Of California / San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • UC San Diego Medical Center - Hillcrest
    San Diego, California 92103, United States
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Swedish Investigational Drug Services Pharmacy
    Seattle, Washington 98104, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Dec 2017, 26 months.

Results were first posted in Jul 2019, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2015
First posted
Jul 29, 2015
StartActual
Oct 2015
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Results first posted
Jul 1, 2019
Last update
Jul 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02511184
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 29, 2015
Start date
Oct 2015
Primary completion
Dec 2017
Completion
Dec 2017
Results posted
Jul 1, 2019
Last update
Jul 1, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion